Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoxyDOT Study
PACTR202401619811584Phase 4Not yet recruiting
- Sponsor
- University of Washington
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of doxycycline in sexually transmitted disease (STD) and Chlamydia trachomatis infection (2 arms), sponsored by University of Washington. Primary endpoint: Percentage of completed doses of weekly doxycycline DOT. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
doxycycline
03
Conditions
sexually transmitted disease (STD)Chlamydia trachomatis infection
Beyond the preview
Go deeper on PACTR202401619811584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202401619811584.